TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01809327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
Study: NCT01802294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa.
Study: NCT04802928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 milligram
Description: Tablets 150 milligram b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03712670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: monthly intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: monthly intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: monthly intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pranoprofen
Description: 0.1% pranoprofen 3 times a day topical eye drops administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carotenoids
Description: daily supplementation of nutraceutical tablets containing the AREDS2 formulation
Study: NCT00779818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Description: Treatment by electrical acupuncture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Treatment by laser
Study: NCT03864627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106
Description: MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
Study: NCT03452995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHYSIOTHERAPY
Description: Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHYSIOTHERAPY
Description: Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHYSIOTHERAPY
Description: Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
Study: NCT02106845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Once daily orally 160 mg (4 tablets 40 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Once daily orally 160 mg (4 tablets 40 mg)
Study: NCT03821350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information leaflet
Description: The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
Study: NCT01199198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Starting dose 15 mg by mouth once a day for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth once a day for 14 days.
Study: NCT02766049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC
Description: Autologous dendritic cells (3x10e7)
Study: NCT02179268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50mg, 50-150mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50mg, 50-150mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50mg, 50-150mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50mg, 50-150mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20mg, 20-40mg/d,qd,for one year
Study: NCT03920579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386 formulation 2
Description: A single oral dose of 1 tablet under fasting conditions for each period
Study: NCT02766049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC10e6+HIV-AT2
Description: Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC10e7+HIV-AT2
Description: Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
Study: NCT02179268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20mg, 20-40mg/d,qd,for one year
Study: NCT02468687

Intervention type: DRUG
Group type: OTHER
Intervention: N-methyl-pyrrolidone
Description: NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
Study: NCT04170491

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous EEG
Description: Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
Study: NCT00865995

Intervention type: PROCEDURE
Intervention: Tracheal Lavage
Description: Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
Study: NCT02179268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20mg, 20-40mg/d,qd,for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20mg, 20-40mg/d,qd,for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine,25mg, 75-100mg/d, bid, for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine,25mg, 75-100mg/d, bid, for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine,25mg, 75-100mg/d, bid, for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: venlafaxine,25mg, 75-100mg/d, bid, for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reboxetine
Description: reboxetine,4mg, 4-8mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reboxetine
Description: reboxetine,4mg, 4-8mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reboxetine
Description: reboxetine,4mg, 4-8mg/d,qd for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reboxetine
Description: reboxetine,4mg, 4-8mg/d,qd for one year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 50min, every week for three months, every month, for nine months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 50min, every week for three months, every month, for nine months
Study: NCT02089035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA-rich dairy products (UHT milk, cheese and butter)
Study: NCT02179268

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 50min, every week for three months, every month, for nine months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 50min, every week for three months, every month, for nine months
Study: NCT04210037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m˄2 on days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m˄2 on days 1 and 8 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m˄2 on days 1 and 8 of a 21-day cycle
Study: NCT02210442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educaguia intervention
Description: Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
Study: NCT03746470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction preserving insertion
Description: Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction detaching insertion
Description: Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
Study: NCT02587169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib-adriamycin
Description: The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
Study: NCT02517892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study: NCT02089035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional dairy products (UHT milk, cheese, butter)
Study: NCT02940132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC10914
Description: SC10914 will be administered orally.
Study: NCT03040700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myocardial Perfusion Scan
Description: Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Description: Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
Study: NCT02145052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous suture
Description: A continuous suture is considered standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture
Description: Interrupted sutures are considered standard of care.
Study: NCT01963182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT01884324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Delivery
Description: This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion.
Study: NCT02456207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT400
Study: NCT00506792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAU145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01504958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS.
Study: NCT02456207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study: NCT02520869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: swim-up technique
Description: swim-up technique used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zeta test technique
Description: zeta test technique used
Study: NCT00428571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gastric bypass surgery
Description: Laparoscopic Gastric Bypass Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic adjustable gastric banding
Description: laparoscopic adjustable gastric banding

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intensive Medical Management
Description: lifestyle, diet, medication optimization
Study: NCT02217423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy chest wall expansion
Description: chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy chest wall expansion
Description: chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy airway clearance modality
Description: The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy airway clearance modality
Description: The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
Study: NCT04791215

Intervention type: OTHER
Intervention: Observational
Description: All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
Study: NCT01504958

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NICE Cognitive Training
Description: 12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: NICE Cognitive Training
Description: 12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: NICE Cognitive Training
Description: 12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group.
Study: NCT00804128

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI

Intervention type: DRUG
Intervention: Gadavist
Description: Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging